ChinaBio Partnering Forum EBD GroupChinaBIO
Share:
Email this page Share this on LinkedIn Share this on Twitter

ChinaBio® Partnering Forum 2015 Press Releases

October 27, 2014ChinaBio® Partnering Forum 2015 to be held in Shanghai, China April 22–23, 2015International pharma and biotech dealmakers consider event critical for cross-border BD
The 2015 edition of ChinaBio® Partnering Forum, China's premier life science partnering event, will be held April 22–23 in Shanghai. Shanghai is the largest city proper in the world and home to over 1,000 life science companies. In 2014, the Forum was attended by 848 delegates from 425 companies and 25 countries, making it the largest partnering conference in China. Phar...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

November 11, 2014 Bayer committed to Open Innovation and Collaborators The Head of Global Drug Discovery at Bayer HealthCare and a Member of the Executive Committee, Andreas Busch described the strategy underlying partnering efforts that he said have delivered a very significant value to patients as well as to shareholders. more ►

November 11, 2014 Merck Serono embraces partnering in all its forms Executive VP and Head of Global Research and Development at Merck Serono, Luciano Rossetti is also a Member of the Executive Committee who joined the company in late July this year. He offered to share with the audience a perspective from what he called a brief tenure. more ►

November 11, 2014 European biotech poised for acceleration David Loew is Senior VP for Commercial Operations in Europe at Sanofi. Rather than focusing on the company, Loew turned the spotlight on a wider concern for promoting a stronger environment for biotechs and start-ups in Europe. more ►

November 11, 2014 Transformational deals that shaped the industry in 2014 Led by moderator David Stubbs, the Managing Director for Inverness Advisors, the goal for the panel was to provide insights for transformational deals of the past year. The session was led off by a truly transformational deal that saw the USD 14.2 billion divestiture by Merck of its consumer healthcare business to Bayer HealthCare in May, 2014. The deal makes Bayer the second-biggest over-the-counter drug maker behind Johnson & Johnson. more ►

November 11, 2014 Covagen and vasopharm: Driving the right deal from the sell side A partner with the law firm Dentons, Peter Homberg teased out insights from the executives of two biotechs who are on the leading edge of negotiations with large pharma companies, providing first-hand accounts of their experiences. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD Group, Inc.
Privacy Policy
Terms of Use
ChinaBio Partnering Forum EBD GroupChinaBIO